228 related articles for article (PubMed ID: 17984802)
1. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions.
Siegrist CA; Lewis EM; Eskola J; Evans SJ; Black SB
Pediatr Infect Dis J; 2007 Nov; 26(11):979-84. PubMed ID: 17984802
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events.
Callréus T; Svanström H; Nielsen NM; Poulsen S; Valentiner-Branth P; Hviid A
Vaccine; 2009 May; 27(22):2954-8. PubMed ID: 19428906
[TBL] [Abstract][Full Text] [Related]
3. Health problems most commonly diagnosed among young female patients during visits to general practitioners and gynecologists in France before the initiation of the human papillomavirus vaccination program.
Van Ganse E; Letrilliart L; Borne H; Morand F; Robain M; Siegrist CA
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):261-8. PubMed ID: 22052698
[TBL] [Abstract][Full Text] [Related]
4. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.
van Klooster TM; Kemmeren JM; van der Maas NA; de Melker HE
Vaccine; 2011 Jun; 29(28):4601-7. PubMed ID: 21549785
[TBL] [Abstract][Full Text] [Related]
5. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
Harper DM
Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
[TBL] [Abstract][Full Text] [Related]
6. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
Watson M; Shaw D; Molchanoff L; McInnes C
Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System.
Borja-Hart NL; Benavides S; Christensen C
Ann Pharmacother; 2009 Feb; 43(2):356-9. PubMed ID: 19155346
[TBL] [Abstract][Full Text] [Related]
8. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.
Verstraeten T; Descamps D; David MP; Zahaf T; Hardt K; Izurieta P; Dubin G; Breuer T
Vaccine; 2008 Dec; 26(51):6630-8. PubMed ID: 18845199
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.
Chao C; Klein NP; Velicer CM; Sy LS; Slezak JM; Takhar H; Ackerson B; Cheetham TC; Hansen J; Deosaransingh K; Emery M; Liaw KL; Jacobsen SJ
J Intern Med; 2012 Feb; 271(2):193-203. PubMed ID: 21973261
[TBL] [Abstract][Full Text] [Related]
10. CNS demyelination and quadrivalent HPV vaccination.
Sutton I; Lahoria R; Tan I; Clouston P; Barnett M
Mult Scler; 2009 Jan; 15(1):116-9. PubMed ID: 18805844
[TBL] [Abstract][Full Text] [Related]
11. Introducing human papillomavirus vaccines - questions remain.
Paavonen J; Lehtinen M
Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
[TBL] [Abstract][Full Text] [Related]
12. Adverse events following HPV vaccination, Alberta 2006-2014.
Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
[TBL] [Abstract][Full Text] [Related]
13. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
[TBL] [Abstract][Full Text] [Related]
14. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus and the HPV vaccine: are the benefits worth the risks?
Knudtson M; Tiso S; Phillips S
Nurs Clin North Am; 2009 Sep; 44(3):293-9. PubMed ID: 19683091
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent HPV vaccination reactions--more hype than harm.
Douglas RJ
Aust Fam Physician; 2009 Mar; 38(3):139-42. PubMed ID: 19283255
[TBL] [Abstract][Full Text] [Related]
17. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
[TBL] [Abstract][Full Text] [Related]
18. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.
Grimaldi-Bensouda L; Rossignol M; Koné-Paut I; Krivitzky A; Lebrun-Frenay C; Clet J; Brassat D; Papeix C; Nicolino M; Benhamou PY; Fain O; Costedoat-Chalumeau N; Courcoux MF; Viallard JF; Godeau B; Papo T; Vermersch P; Bourgault-Villada I; Breart G; Abenhaim L;
J Autoimmun; 2017 May; 79():84-90. PubMed ID: 28190705
[TBL] [Abstract][Full Text] [Related]
19. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
Ault K; Reisinger K
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
[TBL] [Abstract][Full Text] [Related]
20. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies.
Klein NP; Ray P; Carpenter D; Hansen J; Lewis E; Fireman B; Black S; Galindo C; Schmidt J; Baxter R
Vaccine; 2010 Jan; 28(4):1062-8. PubMed ID: 19896453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
